TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16047223
Drug: Levamisole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 2.5 mg/kg on alternate days
Study: 16047223
Drug: I.V. cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. cyclophosphamide 500 mg/m2/month for six months
Study: 10820175
Drug: 15 mg/d
Normalized name: Valtoco, 15 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/d folic acid
Study: 10820175
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d folic acid
Study: 10820175
Drug: 60 mg/d
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/d folic acid
Study: 10820175
Drug: 60 mg/d
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/d folic acid in MTHFR 677TT genotype patients
Study: 10820175
Drug: 30 or
Normalized name: Oseni 25/30 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 or 60 mg/d folic acid
Study: 1514338
Drug: Intermittent wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent wound infiltration with bupivacaine and continuous coeliac plexus blockade (total 862.5 mg over 12 h)
Study: 6341873
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral taurine administration
Study: 29943100
Drug: Sub-tenon steroid
Normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-tenon steroid injection (Triamcinolone acetonide) plus anti-VEGF injection
Study: 29943100
Drug: Anti-VEGF injection
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF injection only
Study: 27112245
Drug: Simethicone addition
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone addition group (400 mg)
Study: 27112245
Drug: Water addition
Normalized name: WATER 99 mL in 100 mL OPHTHALMIC LIQUID [Water Additive]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water addition group (1 L)
Study: 11980869
Drug: Granulocyte colony
Normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte colony stimulating factor (G-CSF, 300 microg)
Study: 6982270
Drug: Cold cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold cardioplegia with topical deep hypothermia using Bretschneider solution
Study: 31192515
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (NGF) injection into the right masseter muscle
Study: 31192515
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (IS) injection into the right masseter muscle
Study: 26950019
Drug: Carbamazepine, Lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine, Lithium Carbonate, or Valproic Acid (monotherapy)
Study: 25426786
Drug: Topical +
Normalized name: Topicale
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical + intrasulcular hyaluronan gel
Study: 25426786
Drug: Topical hyaluronan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hyaluronan gel
Study: 25426786
Drug: Scaling +
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling + topical hyaluronan gel
Study: 18386255
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Pycnogenol daily (oral capsules)
Study: 15218810
Drug: Intramuscular interferon-beta
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon-beta Ia
Study: 9424007
Drug: Nicotinamide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (80 mg/kg/day)
Study: 8479489
Drug: Atovaquone (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone (750 mg, orally, three times daily for 21 days)
Study: 8479489
Drug: Trimethoprim (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (320 mg) plus sulfamethoxazole (1600 mg, orally, three times daily for 21 days)
Study: 15800019
Drug: Half-dose reteplase
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose reteplase plus abciximab
Study: 15800019
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (standard-dose reteplase and half-dose reteplase plus abciximab)
Study: 2679829
Drug: Ossein-hydroxyapatite compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ossein-hydroxyapatite compound (OHC) treatment providing 1.6 g calcium, 0.74 g phosphorus, and 1.94 g noncollagen peptides per day
Study: 2679829
Drug: Ossein-hydroxyapatite compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ossein-hydroxyapatite compound (OHC) treatment
Study: 4157353
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin (single injection)
Study: 23580109
Drug: Pirfenidone single
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone single doses (200, 400, and 600 mg)
Study: 23580109
Drug: Pirfenidone multiple
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone multiple doses (400 mg, 3 times daily)
Study: 23580109
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of pirfenidone
Study: 23580109
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of unchanged pirfenidone
Study: 19762765
Drug: IVRA lidocaine
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVRA lidocaine and paracetamol (300 mg) admixture plus IV saline (Group 2)
Study: 19762765
Drug: IVRA lidocaine
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVRA lidocaine plus IV paracetamol (300 mg) (Group 3)
Study: 14665887
Drug: 1 mmol/l
Normalized name: cardiopleg/organ preserv no.1 9 mmol-198 mmol-2 mmol-1 mmol/L PERFUSION BOTTLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mmol/l CAP diluted in glucidic solvent
Study: 14665887
Drug: 100 nMol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 nMol/l RTX diluted in 10% ethanol
Study: 11197264
Drug: Mesalamine therapy
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine therapy (4 g daily for 18 months)
Study: 11197264
Drug: Mesalamine therapy
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine therapy (in subgroup with isolated small bowel Crohn's disease)
Study: 9250794
Drug: Somatostatin receptor
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin receptor scintigraphy (110 or 220 MBq of 111In‐pentetreotide)
Study: 9425399
Drug: Somatostatin receptor
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin receptor scintigraphy
Study: 28527646
Drug: Tight glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glucose control (4-6 mmol/l, IV insulin, n = 9)
Study: 28527646
Drug: Standard glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glucose control (6-10 mmol/l, SC insulin, n = 9)
Study: 26179771
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg teriparatide (PTH 1-34 (Forteo)) for 4 weeks
Study: 19140845
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 or 3 times per week administration of epoetin-beta)
Study: 8878339
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light treatment administered when well
Study: 8878339
Drug: No bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bright light treatment until first symptoms of depression
Study: 1300312
Drug: Nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100 mg, two tablets a day for 90 days)
Study: 31722024
Drug: Intranasal naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal naloxone hydrochloride 800 μg per 1 mL
Study: 31722024
Drug: Intramuscular naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular naloxone hydrochloride 800 μg per 1 mL
Study: 19461552
Drug: TENS (45-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS (45-min treatment, sensory, biphasic square wave stimulation, 150-mus phase duration, 150 pps)
Study: 19461552
Drug: Focal knee
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal knee joint cooling (20-min treatment with two 1.5-L ice bags)
Study: 17717439
Drug: Standard burn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard burn care plus oxandrolone (0.1 mg/kg body weight q.12 hours p.o, n = 45)
Study: 742355
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with Melfalan (Group A)
Study: 742355
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with adriamycin and Melfalan (Group B)
Study: 742355
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with Melfalan (Group A) among premenopausal patients
Study: 742355
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with adriamycin and Melfalan (Group B) among premenopausal patients
Study: 742355
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with Melfalan (Group A) among postmenopausal patients
Study: 742355
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with adriamycin and Melfalan (Group B) among postmenopausal patients
Study: 6981171
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) 320 mg of TMP and 1,600 mg of SMZ daily for 14 days
Study: 6981171
Drug: Chloramphenicol 2
Normalized name: chloramphenicol 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol 2 g daily for 14 days
Study: 20400416
Drug: Topical alkane
Normalized name: C12-19 alkane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical alkane vapocoolant spray
Study: 17592908
Drug: Psychoeducational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational group therapy
Study: 15273528
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg b.i.d. (n = 198)
Study: 15273528
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg b.i.d. (n = 198)
Study: 9342601
Drug: Lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1 mg bid)
Study: 8518523
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (6 mg/kg/day)
Study: 8518523
Drug: Cyclophosphamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (2.5 mg/kg/day)
Study: 8518523
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (children in complete remission and off therapy)
Study: 17943573
Drug: Intranasal ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal ciclesonide 200 microg once daily
Study: 17943573
Drug: HFA‐BDP 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA‐BDP 320 microg twice daily during run-in period
Study: 17943573
Drug: Dexamethasone 2
Normalized name: dexamethasone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 2 mg on last treatment day
Study: 11599064
Drug: Injection rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection rate of 0.5 mL/second
Study: 11599064
Drug: Injection rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection rate of 1.5 mL/second
Study: 11599064
Drug: Higher injection
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher injection rates (0.5, 1.5, and 3.0 mL/second) in volunteers
Study: 9725493
Drug: Milnacipran (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (50 mg oral and intravenous doses)
Study: 7528939
Drug: Nasal decongestant
Normalized name: Nasal Decongestant
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal decongestant and position
Study: 7528939
Drug: Nasal decongestant
Normalized name: Nasal Decongestant
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal decongestant alone
Study: 7528939
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nasal decongestant and position
Study: 3169044
Drug: Treatment (quinidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (quinidine, disopyramide or mexiletine)
Study: 23512974
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (reduction of daily caloric intake by 400 kcal for 6 months)
Study: 19553555
Drug: N. lactamica
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. lactamica OMV vaccine
Study: 9797642
Drug: Sucrose polyester
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose polyester (SPE) 20-40 g daily (mean 26.8 g)
Study: 2545640
Drug: Dietary fibre
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fibre supplement of 7 g/day for 11 weeks (part I)
Study: 2545640
Drug: Dietary fibre
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fibre supplement of 6 g/day for 16 weeks (part II)
Study: 2545640
Drug: Dietary fibre
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fibre supplement of 6 g/day and an ad libitum diet for the rest of the period (part III)
Study: 1102879
Drug: Sustained-release 40
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release 40 mg dicyclomine hydrochloride tablets (Merbentyl Dospan)
Study: 1102879
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg plain dicyclomine hydrochloride tablets (Merbentyl)
Study: 31775518
Drug: N‐acetylcysteine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐acetylcysteine with a combination of nutraceuticals
Study: 17106751
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of ifosfamide 3 g/m2/day for 3 days (9 g/m2/cycle)
Study: 17106751
Drug: Short (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short (3 h) infusion of ifosfamide 3 g/m2/day for 3 days (9 g/m2/cycle)
Study: 17106751
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of ifosfamide
Study: 17106751
Drug: Short (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short (3 h) infusion of ifosfamide
Study: 14713402
Drug: Intermittent human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent human parathyroid hormone (PTH) - teriparatide (recombinant human PTH 1‐34), self-administered daily injections.
Study: 11488370
Drug: Long-term antidepressant
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antidepressant treatment
Study: 11488370
Drug: Mood-stabilizing agents
Normalized name: CAPILLARY STABILIZING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood-stabilizing agents alone
Study: 11488370
Drug: Mood-stabilizing agents
Normalized name: CAPILLARY STABILIZING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood-stabilizing agents combined with antidepressants
Study: 10511413
Drug: Azithromycin (8.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (8.0 g total dose over 1 month)
Study: 2068440
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (5 mg/kg/d)
Study: 2068440
Drug: Azathioprine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2 mg/kg/d)
Study: 29628196
Drug: Standardized knee
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized knee injection cocktail and oral acetaminophen (standard group)
Study: 29628196
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine periarticular injection and oral acetaminophen (LB group)
Study: 29628196
Drug: Standardized knee
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized knee injection cocktail and intravenous (IV) acetaminophen (IVA group)
Study: 28273870
Drug: Fiber cookie
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber cookie (24 g fiber from distarch phosphate)
Study: 28273870
Drug: Control cookie
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cookie (0.5 g fiber)
Study: 19112278
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate infusion (4 mmol/kg)
Study: 15517671
Drug: Periurethral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periurethral injection
Study: 15517671
Drug: Transurethral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral injection
Study: 10514756
Drug: Musical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Musical therapy
Study: 10514756
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no musical therapy)
Study: 8056006
Drug: Heparin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (100 U.kg‐1 intravenously bolus before thrombolytic treatment and additional intravenous heparin to raise partial thromboplastin time to 2-2.5 times normal)
Study: 8056006
Drug: Heparin (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (Group 1)
Study: 8056006
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no heparin, Group 2)
Study: 25891021
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS (2 mA amplitude, 20 min daily for 5 days)
Study: 11137262
Drug: Meningococcal group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal group C/CRM (197) conjugate vaccine (3 doses at 2, 3, and 4 months)
Study: 9543786
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (3 doses)
Study: 11137262
Drug: Meningococcal group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal group C/CRM (197) conjugate vaccine
Study: 9087155
Drug: Nonsteroidal antiinflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal antiinflammatory drugs (excluding those reported by the patient as responsible for previous reactions)
Study: 9087155
Drug: Pyrazole derivatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrazole derivatives (most common nonsteroidal antiinflammatory drugs involved)
Study: 17476567
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion
Study: 3300120
Drug: Metronidazole-gentamicin (M-G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole-gentamicin (M-G)
Study: 26932256
Drug: Tissue tolerable
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue tolerable plasma (TTP) administered six times each 7 days
Study: 26932256
Drug: Control (nystatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (nystatin, chlorhexidine and placebo treatment)
Study: 26573041
Drug: GnRH Agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH Agonist Microdose Flareup (MF)
Study: 26573041
Drug: GnRH Antagonist/Letrozole
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH Antagonist/Letrozole (AL)
Study: 23840403
Drug: HAART and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART and TB treatment
Study: 22024700
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral levofloxacin
Study: 2707923
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral ciprofloxacin
Study: 22024700
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg levofloxacin and 250 mg ciprofloxacin co-administered
Study: 16493496
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (4 g daily)
Study: 16493496
Drug: corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: corn oil (4 g daily)
Study: 12867313
Drug: 1-l volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-l volume air pocket
Study: 12867313
Drug: 2-l volume
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-l volume air pocket
Study: 10606835
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg daily
Study: 9107154
Drug: Meta-chlorophenylpiperazine (m-CPP)
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meta-chlorophenylpiperazine (m-CPP) infusion (0.08 mg/kg)
Study: 3902199
Drug: Cisplatin (CACP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CACP) + 5-fluorouracil (5-FU) infusion (CACP 100 mg/m2 day 1 and 5-FU 1000 mg/m2 24-hour infusion days 1-4)